ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.

ONXX Onyx Pharmaceuticals, Inc. (MM)

124.70
0.00 (0.00%)
29 Jul 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type
Onyx Pharmaceuticals, Inc. (MM) NASDAQ:ONXX NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 124.70 0 01:00:00

Faruqi & Faruqi, LLP, Partner Juan E. Monteverde Launches an Investigation of Onyx Pharmaceuticals, Inc. Over the Proposed Sa...

29/08/2013 12:00am

Business Wire


Onyx Pharmaceuticals, Inc. (MM) (NASDAQ:ONXX)
Historical Stock Chart


From Jul 2019 to Jul 2024

Click Here for more Onyx Pharmaceuticals, Inc. (MM) Charts.

Juan E. Monteverde, a partner at Faruqi & Faruqi, LLP, a leading national securities firm headquartered in New York City, is investigating the Board of Directors of Onyx Pharmaceuticals (“Onyx” or the “Company”) (NasdaqGS:ONXX) for potential breaches of fiduciary duties in connection with their conduct related to the sale of the Company to Amgen Inc. (NasdaqGS:AMGN) in a deal valued at $10.4 billion. Under the terms of the proposed transaction, Onyx’s stockholders will receive $125 in cash for each share of Onyx common stock they own, while according to Yahoo! Finance, there has been at least one financial analyst that set a price target of $160.00 for Onyx.

Request more information now by clicking here: www.faruqilaw.com/ONXX. There is no cost or obligation to you.

The investigation focuses on whether Onyx’s Board of Directors breached their fiduciary duties to the Company’s stockholders by failing to conduct an adequate and fair sales process prior to agreeing to this proposed transaction, whether and by how much this proposed transaction undervalues the Company to the detriment of Onyx’s shareholders.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm’s clients.

If you own common stock in Onyx and wish to obtain additional information and protect your investments free of charge, please visit us at www.faruqilaw.com/ONXX or contact Juan E. Monteverde, Esq. either via e-mail at jmonteverde@faruqilaw.com or by telephone at (877) 247-4292 or (212) 983-9330.

Attorney Advertising. (C) 2013 Faruqi & Faruqi, LLP. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We are happy to discuss your particular case.

1 Year Onyx Pharmaceuticals, Inc. (MM) Chart

1 Year Onyx Pharmaceuticals, Inc. (MM) Chart

1 Month Onyx Pharmaceuticals, Inc. (MM) Chart

1 Month Onyx Pharmaceuticals, Inc. (MM) Chart

Your Recent History

Delayed Upgrade Clock